AU2006231557B2 - A method and composition for nutritionally improving glucose control and insulin action - Google Patents

A method and composition for nutritionally improving glucose control and insulin action Download PDF

Info

Publication number
AU2006231557B2
AU2006231557B2 AU2006231557A AU2006231557A AU2006231557B2 AU 2006231557 B2 AU2006231557 B2 AU 2006231557B2 AU 2006231557 A AU2006231557 A AU 2006231557A AU 2006231557 A AU2006231557 A AU 2006231557A AU 2006231557 B2 AU2006231557 B2 AU 2006231557B2
Authority
AU
Australia
Prior art keywords
fat
composition
protein
nutritional formulation
carbohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2006231557A
Other languages
English (en)
Other versions
AU2006231557A1 (en
Inventor
Gianni Biolo
Anne L. Falk
Norman Alan Greenberg
Kenneth C. Hayes
John P. Troup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36661519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2006231557(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec SA filed Critical Nestec SA
Publication of AU2006231557A1 publication Critical patent/AU2006231557A1/en
Assigned to NESTEC S.A. reassignment NESTEC S.A. Request for Assignment Assignors: NOVARTIS AG
Priority to AU2010202933A priority Critical patent/AU2010202933A1/en
Application granted granted Critical
Publication of AU2006231557B2 publication Critical patent/AU2006231557B2/en
Assigned to Société des Produits Nestlé S.A. reassignment Société des Produits Nestlé S.A. Request for Assignment Assignors: NESTEC S.A.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Obesity (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pediatric Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
AU2006231557A 2005-04-06 2006-04-04 A method and composition for nutritionally improving glucose control and insulin action Expired AU2006231557B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010202933A AU2010202933A1 (en) 2005-04-06 2010-07-12 A method and composition for nutritionally improving glucose control and insulin action

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66863305P 2005-04-06 2005-04-06
US60/668.633 2005-04-06
PCT/US2006/012576 WO2006108008A2 (en) 2005-04-06 2006-04-04 A method and composition for nutritionally improving glucose control and insulin action

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010202933A Division AU2010202933A1 (en) 2005-04-06 2010-07-12 A method and composition for nutritionally improving glucose control and insulin action

Publications (2)

Publication Number Publication Date
AU2006231557A1 AU2006231557A1 (en) 2006-10-12
AU2006231557B2 true AU2006231557B2 (en) 2010-09-09

Family

ID=36661519

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2006231557A Expired AU2006231557B2 (en) 2005-04-06 2006-04-04 A method and composition for nutritionally improving glucose control and insulin action
AU2010202933A Abandoned AU2010202933A1 (en) 2005-04-06 2010-07-12 A method and composition for nutritionally improving glucose control and insulin action

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010202933A Abandoned AU2010202933A1 (en) 2005-04-06 2010-07-12 A method and composition for nutritionally improving glucose control and insulin action

Country Status (16)

Country Link
US (2) US8067359B2 (enExample)
EP (3) EP1868454B1 (enExample)
JP (3) JP5788631B2 (enExample)
CN (2) CN105394748A (enExample)
AU (2) AU2006231557B2 (enExample)
BR (1) BRPI0608610A2 (enExample)
CA (1) CA2601427C (enExample)
DK (1) DK1868454T3 (enExample)
ES (1) ES2419205T3 (enExample)
IL (1) IL186005A0 (enExample)
MX (1) MX2007012450A (enExample)
PT (1) PT1868454E (enExample)
RU (1) RU2421076C2 (enExample)
SG (1) SG161234A1 (enExample)
WO (1) WO2006108008A2 (enExample)
ZA (1) ZA200707825B (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283327B2 (en) 2005-03-19 2012-10-09 Kneller Bruce W Palatinose for enhancing dietary supplement and pharmaceutical delivery
DK1868454T3 (da) * 2005-04-06 2013-04-02 Nestec Sa Sammensætning til ernæringsmæssig forbedring af glucosekontrol og insulinvirkning
WO2007140230A2 (en) * 2006-05-26 2007-12-06 Nestec S.A. Methods of use and nutritional compositions of touchi extract
WO2008054193A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Nutritional products that comprise saccharide oligomers
KR101243406B1 (ko) * 2008-01-09 2013-03-13 뉴트리 가부시키가이샤 암 화학 요법시에 일어나는 산화 스트레스 및/또는 부작용의 경감 혹은 암 화학 요법시의 영양 상태를 개선하기 위한 조성물
US8071143B2 (en) * 2008-04-02 2011-12-06 Brandeis University Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances
ES2583602T3 (es) * 2008-05-07 2016-09-21 Vegenat, S.A. Mezcla de hidratos de carbono y su utilización para preparar un producto destinado a la alimentación oral o enteral
WO2009135959A1 (es) * 2008-05-07 2009-11-12 Katry Inversiones, S.L. Producto alimenticio para la nutrición por vía enteral u oral del paciente diabético
US9345731B2 (en) 2008-08-27 2016-05-24 Pt. Dexa Medica Herbal extract as sensitivity enhancer toward insulin and antidiabetes
CA2744100C (en) 2008-10-21 2020-06-30 The General Hospital Corporation Cell transplantation
US8114445B2 (en) * 2008-11-07 2012-02-14 Reliv International Inc. Dietary supplement for promoting wellness and weight loss and methods of administering the same
US20100179089A1 (en) * 2009-01-13 2010-07-15 Deutz Nicolaas E P Compositions and Methods to Manage the Inflammatory Basis of Chronic Disease Conditions and Maintain an Optimal Immune Response in Elderly
SG10201901259RA (en) 2009-02-24 2019-03-28 Ritter Pharmaceuticals Inc Prebiotic formulations and methods of use
EP2411033B1 (en) 2009-03-24 2015-03-04 Universiti Putra Malaysia Anti-diabetic nutraceutical composition from palm leaf extract
EP2311486A1 (en) * 2009-10-07 2011-04-20 Nestec S.A. GLP-2 for use in intestine and muscle recovery
WO2012161670A2 (en) 2010-04-07 2012-11-29 Incube Labs, Llc Method for treating diabetes and other glucose regulation disorders using stem cells
US20130202733A1 (en) * 2010-07-14 2013-08-08 Suedzucker Aktiengesellschaft Mannheim/Ochsenfurt Isomaltulose for use in enhancing mental performance
KR101809301B1 (ko) 2010-08-06 2018-01-18 더 제너럴 하스피털 코포레이션 두잉 비즈니스 애즈 매사츄세츠 제너럴 하스피털 세포 처리 시스템 및 장치
CN101926431A (zh) * 2010-08-23 2010-12-29 贵阳高新创嘉创业服务有限公司 一种具有保健功能的组合物及其制备方法和用途
CN102007952A (zh) * 2010-09-26 2011-04-13 深圳职业技术学院 营养棒及其制备方法
PH12014500268A1 (en) * 2011-08-16 2014-03-31 Abbott Lab Nutritional compositions comprising a soluble viscous fiber and a polyphenol-containing plant extract
US20150017309A1 (en) * 2012-03-13 2015-01-15 Sapporo Holdings Limited Nutritionally balanced food or beverage product
WO2013173719A1 (en) * 2012-05-18 2013-11-21 Metaproteomics, Llc Phytonutrient compositions and methods of use
WO2014124140A1 (en) 2013-02-06 2014-08-14 Brandeis University Treatment of dna damage and mitochondrial dysfunction using palm fruit juice
AU2014284399B2 (en) 2013-07-01 2017-10-26 University Of Southern California Fasting condition as dietary treatment of diabetes
ITMI20131467A1 (it) * 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
WO2015074102A1 (en) * 2013-11-19 2015-05-28 Omniblend Innovation Pty Ltd Composition and method for control of post-prandial glucose
WO2015109231A1 (en) * 2014-01-17 2015-07-23 Cornell University Methods of treating metabolic syndrome related conditions using retinoic acid receptor agonists
US11191755B2 (en) 2014-01-17 2021-12-07 Cornell University Compositions and methods for providing cardioprotective effects
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
JP2019504073A (ja) * 2016-01-12 2019-02-14 ユニバーシティ オブ サザン カリフォルニア 多発性骨髄腫及び他のがんに対する食事療法としての長期断食模倣の使用
IT201600083376A1 (it) 2016-08-08 2018-02-08 Sofar Spa Uso di probiotici per aumentare l’assorbimento proteico
ITUA20164188A1 (it) 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
EP3468670B1 (en) 2016-06-10 2023-12-13 University of Copenhagen Predetermined diet for use in inducing weight loss and preventing weight gain
WO2017213961A1 (en) * 2016-06-10 2017-12-14 Gelesis Llc Methods of inducing weight loss, treating obesity and preventing weight gain
CN106490614A (zh) * 2016-10-31 2017-03-15 北京万源普达医疗科技有限公司 一种组合物及其作为糖尿病全营养配方食品的应用
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JP7136807B2 (ja) 2017-04-17 2022-09-13 ザ・ユニバーシティ・オブ・シカゴ ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料
US12110562B2 (en) 2017-06-01 2024-10-08 University Of Copenhagen Compositions and methods for predicting and promoting weight loss
SG11202001142VA (en) 2017-08-14 2020-03-30 Axcella Health Inc Amino acid compositions for the treatment of liver disease
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
US11576403B2 (en) * 2018-12-13 2023-02-14 Societe Des Produits Nestle S.A. Methods for enhancing metabolic health in an animal
CN109528734A (zh) * 2019-01-24 2019-03-29 华纳时代健康科技（武汉）股份有限公司 一种复合营养组合物及其制备方法
CN110200276B (zh) * 2019-06-27 2023-04-07 刘东波 基于中药营养的组合物
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
CN116209738B (zh) 2020-09-01 2026-03-13 国际壳牌研究有限公司 发动机油组合物
CN114631628A (zh) * 2020-12-15 2022-06-17 中国科学院上海营养与健康研究所 一种增加血液fgf21浓度的方法
CN114794487A (zh) * 2021-01-22 2022-07-29 中国科学院上海营养与健康研究所 一种治疗糖尿病的方法
CN113785915A (zh) * 2021-08-05 2021-12-14 中山大学 一种甜味敏感的食物配方及其动物模型的构建方法
CN113521277A (zh) * 2021-08-27 2021-10-22 四川力量科技有限公司 一种康复糖尿病的产品及其制备方法
CN116473125A (zh) * 2022-01-17 2023-07-25 内蒙古伊利实业集团股份有限公司 一种缓释碳水组合物以及应用
CN116549428B (zh) * 2023-06-20 2025-05-16 郑州大学 4-羟基异亮氨酸的新用途
WO2026038577A1 (ja) * 2024-08-15 2026-02-19 太陽化学株式会社 飲食品摂取後の血中アミノ酸または消化管ホルモン濃度制御用組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140304A (en) * 1988-09-28 2000-10-31 Eicotech Corporation Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8317248D0 (en) * 1983-06-24 1983-07-27 Wyeth John & Brother Ltd Fat compositions
CA2173780A1 (en) * 1995-06-01 1996-12-02 Randy Grote Method for providing nutrition in a variety of compositional forms
MY115050A (en) * 1995-10-16 2003-03-31 Mead Johnson Nutrition Co Diabetic nutritional product having controlled absorption of carbohydrate
DK0780055T3 (da) * 1995-10-27 2003-03-24 Nestle Sa Nærende kaffesammensætning
ES2179156T3 (es) 1996-11-20 2003-01-16 Nutricia Nv Composicion nutricional que incluye grasas para el tratamiento del sindrome metabolico.
EP1310173B2 (en) 1997-06-23 2014-12-31 Société des Produits Nestlé S.A. Composition for providing nutrition to diabetics
US5932258A (en) * 1998-04-06 1999-08-03 The Iams Company Composition and process for improving glucose metabolism in companion animals
JP2000264844A (ja) * 1999-01-11 2000-09-26 Otsuka Pharmaceut Factory Inc 腎疾患患者用栄養組成物
US6440931B1 (en) * 1999-02-23 2002-08-27 Natural Corporation Conjugated linoleic acid in treatment and prophylaxis of diabetes
US6592863B2 (en) * 2000-08-22 2003-07-15 Nestec S.A. Nutritional composition
WO2002064809A2 (en) * 2001-02-09 2002-08-22 Unilever N.V. Process for the preparation of one or more statins by fermentation
US6605310B2 (en) * 2001-06-06 2003-08-12 Nestec S.A. Calorically dense liquid oral supplement
MY135783A (en) * 2001-09-07 2008-06-30 Meiji Dairies Corp Nutritional composition for controlling blood sugar level
DK1643861T3 (da) * 2003-07-15 2011-07-25 Nestec Sa Fiber- og kalorierig flydende næringssammensætning til tarmsundhed hos ældre patienter
DK1868454T3 (da) * 2005-04-06 2013-04-02 Nestec Sa Sammensætning til ernæringsmæssig forbedring af glucosekontrol og insulinvirkning

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140304A (en) * 1988-09-28 2000-10-31 Eicotech Corporation Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Glucose transport expression promoter for preventing and improving diabetes, insulinemia and insulin resistance, comprises catechin as active ingredient" DERWENT Abstract No: AN 2003-527862, 2003, abstract *
CEFALU WT, WANG ZQ, ZHANG XH, BALDOR LC, RUSSELL JC: "Oral chromium.... rats" J. NUTR., vol. 132, 2002, pages 1107-1114 *
CHEUVRONT SN: "The zone diet phenomenon: a closer look at the science behind the claims" J. AM. Call. NUTR., vol. 22, no. 1, 2003, pages 9-17 *
CLARKE SO: "Polyunsaturated fatty acid regulation of gene transcription: a molecular mechanism to improve the metabolic syndrome" J. NUTR., vol. 131,2001, pages 1129-1132 *
D2: HOWARD G, ET AL: "Insulin sensitivity and atherosclerosis" circulation, VOL.93, 1996, pages 1809-1817 *
DANSINGER Ml, GLEASON JA, GRIFFITH Jl, SElKER HP, SCHAEFER EJ: "Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction" JAMA, vol. 293, no. 1, 5 January 2005, pages 43-53 *
GREENE E L ET AL: "Alpha-Lipoic Acid Prevents The ..... Incubation" METABOLISM, CLINICAL AND EXPERIMENTAL, W.B.SAUNDERS CO., PHILADELPHIA, PA, US, vol. 50, no. 9, September 2001, pages 1063-1069 *
QIN B ET AL: "Cinnamon Extract Prevents The Insulin Resistance Induced By A High-Fructose Diet" HORMONE AND METABOLIC RESEARCH, THIEME-STRATTON, STUTTGART, DE, vol. 36, no. 2, February 2004, pages 119-125 *
TIMAR O ET AL: "METABOLIC SYNDROME X: A REVIEW" CANADIAN JOURNAL OF CARDIOLOGY, PULSUS GROUP, INC, vol. 16, no. 6, June 2000, pages 779-789 *

Also Published As

Publication number Publication date
CN101175416A (zh) 2008-05-07
JP2013100353A (ja) 2013-05-23
EP1868454B1 (en) 2013-03-06
SG161234A1 (en) 2010-05-27
WO2006108008A3 (en) 2007-01-18
DK1868454T3 (da) 2013-04-02
US8067359B2 (en) 2011-11-29
US20110305791A1 (en) 2011-12-15
AU2010202933A1 (en) 2010-07-29
BRPI0608610A2 (pt) 2010-01-19
JP2008535840A (ja) 2008-09-04
US20080193603A1 (en) 2008-08-14
CN105394748A (zh) 2016-03-16
RU2421076C2 (ru) 2011-06-20
MX2007012450A (es) 2008-02-12
RU2007140731A (ru) 2009-05-20
HK1113289A1 (en) 2008-10-03
US8697630B2 (en) 2014-04-15
IL186005A0 (en) 2008-01-20
CA2601427A1 (en) 2006-10-12
AU2006231557A1 (en) 2006-10-12
WO2006108008A2 (en) 2006-10-12
EP2241195A1 (en) 2010-10-20
CA2601427C (en) 2013-06-11
EP1868454A2 (en) 2007-12-26
EP2243383A3 (en) 2011-02-16
ES2419205T3 (es) 2013-08-19
PT1868454E (pt) 2013-04-03
EP2243383A2 (en) 2010-10-27
ZA200707825B (en) 2009-10-28
JP2015187182A (ja) 2015-10-29
JP5788631B2 (ja) 2015-10-07

Similar Documents

Publication Publication Date Title
US8067359B2 (en) Composition for nutritionally improving glucose control and insulin action
Aleixandre et al. Dietary fiber and blood pressure control
Srinivasan Fenugreek (Trigonella foenum-graecum): A review of health beneficial physiological effects
US20090226553A1 (en) Method and composition using irvingia gabonensis for reducing body weight
AU2012261503B2 (en) A method and composition for nutritionally improving glucose control and insulin action
Fouda et al. Effects of Arabic Gum on cardiomyopathy in a rat model of type II diabetes
Chatturong et al. Anti-obesity of dried mulberry fruit powder in mice fed with high-fat diet
HK1113289B (en) Composition for nutritionally improving glucose control and insulin action
Egea et al. Unlocking the Potential of Chia Intake in the Management of Metabolic Syndrome and its Risk Conditions: A Narrative Review
Mehla et al. A Compendium on Various Traditional Plants Used in the Management of Diabetes Mellitus
HK1116999A (en) A method and composition for nutritionally improving glucose control and insulin action
Yoshinari et al. The efficacy and safety of a proprietary onion-pumpkin extract (OPtain120) on blood pressure: an open-label study
Mekky et al. Natural Remedies for Hypercholesteremia
Arumugam et al. Functional Foods in Clinical Trials in the Intervention of Diabetes Complications
Han et al. Biocellulose reduces body weight gain of rats fed high-fat diet
Paul et al. Inositol modulation of essential metabolic pathways of insulin resistance in metabolic syndrome, polycystic ovarian syndrome, and type 2 diabetes
Bajerska et al. The influence of bread en‐riched with bioactive components on body weight control, carbo‐hydrate metabolism, and lipid profile
JP2006290806A (ja) 膵リパーゼ阻害剤及び膵リパーゼ阻害作用を持つ食後高脂血症防止食品
Rezq et al. Some of Biological and Histopathological Effects of Cooked Red and White Beans (Phaseolus Vulgaris L.) Consumption on Obese Rats
Gellenbeck et al. Dietary Bioactive Components
Bloomer et al. Minimizing Postprandial Oxidative Stress in Type 2 Diabetes: The Role of Exercise and Selected Nutrients

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: NESTEC S.A.

Free format text: FORMER APPLICANT(S): NOVARTIS AG

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SOCIETE DES PRODUITS NESTLE S.A.

Free format text: FORMER OWNER(S): NESTEC S.A.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired